Public Health Today—June 5, 2026 - LucidQuest Ventures

• The Pharmaceutical Journal has released a detailed analysis of the new community pharmacy contract. • The report examines whether the new framework will stabilize medicines funding and evaluates its promises regarding long-term systemic reform.

• A new outbreak of the Ebola Bundibugyo virus has emerged, affecting the Democratic Republic of Congo, Uganda, and surrounding neighboring countries. • Pharmaceutical and biotech companies are collaborating with global health and humanitarian partners to coordinate a rapid medical response.

• President Barrow inaugurated the National Food and Drug Quality Control Laboratory in Brusubi to strengthen the country's health infrastructure. • During the ceremony, the President addressed a previous Acute Kidney Injury (AKI) outbreak, describing it as one of the darkest chapters in the nation's recent health history.

• A new study highlights that regular exercise, such as brisk walking or cycling, combined with adequate sleep is linked to improved mental health during midlife. • Separate research on mice indicates that diets rich in polyunsaturated fatty acids (PUFAs), specifically omega-3s from fish oil, significantly slowed cancer development.

• Former President Trump signed an executive order in April titled “Accelerating Medical Treatments for Serious Mental Illness” to fast-track research and drug approvals for psychedelic-assisted therapy. • The order aims to increase clinical trial participation and explore innovative research models to treat serious mental health conditions.

• Federal initiatives have expanded a drug-price transparency tool and proposed a $50 per month access plan for eligible Medicare beneficiaries using GLP-1 medications. • The new pricing proposal is scheduled to take effect in July 2026, though debates continue regarding actual savings and remaining affordability gaps.

• A landmark week in oncology saw pivotal data released for lung, prostate, bladder, and haematological cancers, alongside major capital investments in AI drug discovery, RNA therapeutics, and gene editing. • New data for embolisation-eligible hepatocellular carcinoma (HCC) showed a 30% incremental improvement over TACE, though overall survival (OS) data remains immature.

• An experimental drug called daraxonrasib demonstrated a significant survival benefit for patients with metastatic pancreatic cancer in a global Phase 3 clinical trial. • The study involving 500 patients showed that those receiving daraxonrasib had a median overall survival of 13.2 months, nearly double the 6.7 months seen in the standard chemotherapy group.

• The Africa CDC and World Health Organization (WHO) have launched a joint continental response plan to combat an Ebola outbreak. • Running from June to November 2026, the initiative seeks to raise US$ 518 million to fund rapid detection, clinical care, and emergency coordination.

• Merck & Co. is considering the use of molnupiravir, an antiviral drug previously authorized for COVID-19 treatment, to combat a worsening Ebola outbreak in central Africa. • The move comes as governments and health authorities struggle to respond to the escalating public health crisis in the region.

• UK scientists from the University of Oxford and biotechnology firm Basecamp Research have launched human trials for the world's first AI-designed vaccine. • The vaccine targets Crimean-Congo haemorrhagic fever (CCHF), a potentially fatal viral disease primarily transmitted to humans via tick bites.